Exploring the potential health impact and cost-effectiveness of AIDS vaccine within a comprehensive HIV/AIDS response in lowand middle-income countries

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Harmon, Thomas M ^a   Fisher, Kevin A ^b   McGlynn, Margaret G ^a   Stover, John ^c   Warren, Mitchell J ^b   Teng, Yu ^c   Näveke, Arne ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b Global Advocacy for HIV Prevention   (United States)

^c AVENIR HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; HEALTH IMPACT ASSESSMENT; HEALTH PROGRAM; INFECTION PREVENTION; SENSITIVITY ANALYSIS; VACCINATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; IMMUNOLOGY; POVERTY; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; THEORETICAL MODEL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; MODELS, THEORETICAL; POVERTY; PUBLIC HEALTH;

EID: 84954144766     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146387     Document Type: Article

References (29)

1. UNAIDS. How AIDS Changed Everything: MDG 6:15 Years, 15 Lessons of Hope from the AIDS Response. http://www.unaids.org: 2015 July 2015.
2. UNAIDS. AIDSinfo: Epidemiological status: UNAIDS; 2014 [5 October 2015]. Available from: http://www.unaids.org/en/dataanalysis/datatools/aidsinfo.
3. Pruss-Ustun A, Wolf J, Driscoll T, Degenhardt L, Neira M, Calleja JM. HIV due to female sex work: regional and global estimates. PLoSOne. 2013; 8(5):e63476. doi: 10.1371/journal.pone.0063476 PMID: 23717432
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. doi: 10.1056/NEJMoa1105243 PMID: 21767103
5. Raymond A, Hill A, Pozniak A. Large disparities in HIV treatment cascades between eight European and high-income countries-analysis of break points. Journal of the International AIDS Society. 2014, 17(Suppl3):19507
6. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV.www.who.int. September 2015.
7. UNAIDS. On the Fast-Track to end AIDS by 2030-Focus on location and population (World AIDS Day Report 2015). http://www.unaids.org November 30.
8. Esparza J. Abrief history of the global effort to develop a preventive HIV vaccine. Vaccine. 2013; 31 (35):3502-18. doi: 10.1016/j.vaccine.2013.05.018 PMID: 23707164
9. Lema D, Garcia A, De Sanctis JB. HIV vaccines: a brief overview. Scand J Immunol. 2014; 80(1):1-11. doi: 10.1111/sji.12184 PMID: 24813074
10. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVACandAIDSVAXto prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. doi: 10.1056/NE JMoa0908492 PMID: 19843557
11. National Institute of Allergy and Infectious Diseases. NIH-sponsored HIV vaccine trial launches in South Africa: Early-stage trial aims to build on RV144 results: http://www.nlaid.nih.giv; 2015 [updated 18 February 210523 June 2015]. Available from: http://www.niaid.nih.gov/news/newsreleases/2015/Pages/HVTN100.aspx.
12. IAVIReport. Clinical Trials Database: Database of vaccine candidates in clinical trials: IAVIReport; 2015 [23 June 2015]. Available from: http://www.iavireport.org/Trials-Database/Pages/default.aspx.
13. Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011; 377(9782):2031-2041. doi: 10.1016/S0140-6736(11)60702-2 PMID: 21641026
14. Stover J, Hallett TB, Wu Z, Warren M, Gopalappa C, Pretorius C, et al. How can we get close to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV. PLoSOne 9(11), e111956, L2014. doi: 10.1371/journal.pone.0111956 PMID: 25372770
15. Available via Avenir Institute. http://www.avenirhealth.org/software-spectrummodels.php
16. Stover J, Bollinger L, Hecht R, Williams C, Roca E. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff (Millwood). 2007; 26(4):1147-58.
17. Jit M, Brisson M, Laprise JF, Choi YH. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ. 2015; 350:g7584. doi: 10.1136/bmj.g7584 PMID: 25567037
18. International Association of Providers of AIDS Care. Global HIV Policy Watch: ART eligibility criteria for asymptomatic people living with HIV. [Updated: July 16, 2015] Available From: http://hivpolicywatch.org
19. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: lessons learned and the way forward. CurrOpin HIV AIDS. 2010; 5(5):428-34. doi: 10.1097/COH.0b013e32833d17ac PMID: 20978385
20. AVAC. AIDS vaccine research: An overview: http://www.avac.org; 2015 [updated May 201523 June 2015]. Available from: http://www.avac.org/sites/default/files/event files/HVAD2015 slides.pdf.
21. Hankins CA, Glasser JW, Chen RT. Modeling the impact of RV144-like vaccines on HIV transmission. Vaccine. 2011; 29(36):6069-71. doi: 10.1016/j.vaccine.2011.07.001 PMID: 21762753
22. Levine OS, Knoll MD, Jones A, Walker DG, Risko N, Gilani Z. Global status of Haemophilus influenzae type band pneumococcal conjugate vaccines: evidence, policies, and introductions. CurrOpin Infect Dis. 2010; 23(3):236-41. doi: 10.1097/QCO.0b013e328338c135 PMID: 20407316
23. Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, Ouedraogo R, et al. Impact of the ser-ogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013; 56(3):354-63. doi: 10.1093/cid/cis892 PMID: 23087396
24. Levin A, Wang SA, Levin C, Tsu V, Hutubessy R. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. PLoSOne. 2014; 9(6):e101114. doi: 10.1371/journal.pone.0101114 PMID: 24968002
25. World Health Organization. Macroeconomics and Health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health. 2001 20 December 2001. Report No.: 2001/13984.
26. Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low-and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics. 2014; 32(6):525-31. doi: 10.1007/s40273-014-0162-x PMID: 24791735
27. GAVI: The vaccine alliance. Countries eligible for support: http://www.gavi.org; 2015 [23 June 2015]. Available from: http://www.gavi.org/support/apply/countries-eligible-for-support/.
28. The Henry J. Kaiser Family Foundation and UNAIDS. Financing the Response to HIV in Low-and Middle-Income Countries: International Assistance from Donor Governments in 2014. http://www.unaids. org: 2015 July 2015. Report No.: Contract No.: #7347-11.
29. Harmon T, Guo W, Stover J, Wu Z, Kaufman J, Schneider K, et al. The potential impact of preventive HIV vaccines in China: Results and benefits of a multi-province modeling collaboration. Vaccines. 2015; 3(1):1-19. doi: 10.3390/vaccines3010001 PMID: 26344945